Treats poisoning. Sold as Atropen, Atropine. Every FDA application for this active ingredient: 2 branded and 1 generic.
As of Nov 14, 2026, FDA lists 3 applications for Atropine (sold as Atropen, Atropine), first approved May 15, 1973, with 1 new use approved and 0 published complete response letters.
| Atropine Sulfate | Part B | $186K | +1% | 8,376 |
| ATROPINE SULFATE(J0462) | Part B | $15K | New | 1,031 |
| BRIGHT-LIGHT: Studying Red Light Therapy for Severe Short-Sightedness or Short-Sightedness That Worsens Despite Standard TreatmentMyopia, Myopia Progressing · Singapore National Eye Centre | Not applicable | Not yet recruiting | Nov 6, 2026 |
| Segmental Thoracic vs Lumbar Spinal: Recovery After Elective CesareanCesarean · Adiyaman University Research Hospital | Not applicable | Not yet recruiting | Nov 4, 2026 |
| Oral Gabapentin Versus Intravenous Neostigmine/Atropine Versus Combination of Both for Prevention of PDPHPostdural Puncture Headache (PDPH) · Assiut University | Phase 2 / Phase 3 | Recruiting | Nov 4, 2026 |
| Conscious Sedation Versus General Anesthesia for Pulsed Field Ablation in Paroxysmal Atrial FibrillationParoxysmal Atrial Fibrillation · China National Center for Cardiovascular Diseases | Not applicable | Recruiting | Oct 16, 2026 |
| Early Intervention for High Risk Premyopic ChildrenMyopia · National Yang Ming Chiao Tung University Hospital | Phase 2 | Not yet recruiting | Oct 7, 2026 |
| Control of Myopia in Young Children Using H.O.P.E. Lenses Combined With 0.02% Atropine Eye DropsMyopia · Ruihua Wei | Not applicable | Not yet recruiting | Sep 29, 2026 |
| AI-Stratified Myopia Control for Children in Remote AreasMyopia · Shanghai Eye Disease Prevention and Treatment Center | Not applicable | Not yet recruiting | Sep 17, 2026 |
| Low-Dose Atropine Eye Drops for Excessive Tearing (Epiphora)Epiphora · Rehan Ahmed | Phase 2 | Recruiting | Sep 11, 2026 |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA